KLK3 and neoplasm: Androgen deprivation therapy (ADT) with or without an anti-androgen agent may be given to those patients with rising prostate-specific antigen (PSA) levels to inhibit the signaling of the androgen receptor, which is critical for tumor growth and progression.5